Withdrawal of Epoprostenol Therapy in a Patient with Pulmonary Hypertension Associated with Sjögren's Syndrome

• Published in: Internal Medicine Vol. 53; no. 19; pp. 2237 - 2240
• Main Authors: Fujita, Tetsuo, Tanabe, Nobuhiro, Kasahara, Yasunori, Sugiura, Toshihiko, Sakao, Seiichiro, Tatsumi, Koichiro
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01.01.2014
• Subjects: Administration, Oral; Adult; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - therapeutic use; combination oral therapy; epoprostenol; Epoprostenol - administration & dosage; Epoprostenol - therapeutic use; Female; Humans; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - etiology; Injections, Intravenous; pulmonary arterial hypertension; Sjogren's Syndrome - complications; Sjogren's Syndrome - diagnosis; Sjögren's syndrome; transition; Withholding Treatment

Pulmonary arterial hypertension (PAH) is a rare complication, but a significant prognostic factor in patients with Sjögren's syndrome (SjS). Despite its efficacy, the long-term use of intravenous epoprostenol is sometimes complicated by adverse effects, such as catheter-related infection. This...